Abstract Details

Title Walking Outcomes in Morbidly Obese Multiple Sclerosis Patients Undergoing Bariatric Surgery: A Case-Control Study

Topic MS and Related Diseases

Presentation(s) P04 - (-)

Poster/Presentation
Number 107

Objective

Background BACKGROUND: Bariatric surgery has been shown to either improve or resolve a host of medical and neurological conditions. Literature is sparse however regarding the effect and outcomes of weight reduction surgery on MS patients.

Design/Methods DESIGN/METHODS: We retrospectively identified 22 MS patients with morbid obesity who had undergone bariatric surgery at our institution between 2004 and 2011. Quality of life measures (EQ-5D and PHQ-9) and T25FW values obtained during both the pre-operative and the most recent visit were available for 16 patients and were compared to a matched control sample of non-surgically managed morbidly obese MS patients. T25FW variability, defined as [(T25FW (longest) T25FW (shortest) - 1] x 100, was determined for each patient, with a cut-off of 20% or greater being reflective of significant clinical change, as validated in prior studies.

Results RESULTS: For the surgical cohort, 30-day readmission rate was 9% with a 90-day-complication rate of 13.6% . There were no mortalities and the mean length-of-stay was 4 days. Of the 16 surgical cases who had serial neurologic evaluations, 11 patients (68.75%) showed no change in their walking speed, four patients (25%) exhibited improvement, and one patient experienced slowing. These patients on average were walking 1.96 seconds faster than their non surgical cohort (p-0.017). Among the control sample, 8 (50%) had slowing on serial testing, 7 (44%) showed no change and one patient exhibited improvement. The mean time frame between the two index visits was 39 months for the study sample and 39.8 months for the control. There was no statistically significant difference in the quality of life measures between the two groups.

Conclusions CONCLUSIONS: Bariatric surgery in morbidly obese MS patients leads to significant improvement in walking speed, with no significant changes in the quality of life measures.

Authors/Disclosures
Adham Jammoul, MD (Cleveland Clinic - Hillcrest Hospital) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Alex D. Rae-Grant, MD, FRCPC, FAAN (Ebsco Information Services)	Dr. Rae-Grant has received publishing royalties from a publication relating to health care. Dr. Rae-Grant has received publishing royalties from a publication relating to health care.
Krzysztof W. Selmaj (University of Warmia and Mazury)	Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Astra. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS. Krzysztof W. Selmaj has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.

��ɫ��

��ɫ��